$ENTO
Entero Therapeutics Inc

2024 Q3 Form 10-Q Financial Statement

#000141057824001914 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $207.0K
YoY Change -79.53%
% of Gross Profit
Depreciation & Amortization $1.000K
YoY Change -86.3%
% of Gross Profit
Operating Expenses $1.893M
YoY Change -44.87%
Operating Profit -$1.893M
YoY Change -44.87%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$2.645K
YoY Change 159.06%
Pretax Income -$1.895M
YoY Change -44.74%
Income Tax
% Of Pretax Income
Net Earnings -$2.581M
YoY Change -24.84%
Net Earnings / Revenue
Basic Earnings Per Share -$0.59
Diluted Earnings Per Share -$0.59
COMMON SHARES
Basic Shares Outstanding 4.552M
Diluted Shares Outstanding 4.552M

Balance Sheet

Concept 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $400.0K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $305.5K
Receivables
Other Receivables
Total Short-Term Assets $83.84M
YoY Change 2008.39%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill $1.684M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.978M
YoY Change 1.42%
TOTAL ASSETS
Total Short-Term Assets $83.84M
Total Long-Term Assets $1.978M
Total Assets $85.82M
YoY Change 1347.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.215M
YoY Change 282.35%
Accrued Expenses $219.2K
YoY Change -73.73%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.69M
YoY Change 532.04%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $15.69M
Total Long-Term Liabilities
Total Liabilities $15.77M
YoY Change 495.46%
SHAREHOLDERS EQUITY
Retained Earnings -$190.1M
YoY Change 5.49%
Common Stock $474.00
YoY Change -64.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.369M
YoY Change
Total Liabilities & Shareholders Equity $85.82M
YoY Change 1347.89%

Cashflow Statement

Concept 2024 Q3
OPERATING ACTIVITIES
Net Income -$2.581M
YoY Change -24.84%
Depreciation, Depletion And Amortization $1.000K
YoY Change -86.3%
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
fwbi Class Of Warrant Or Right Expired Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExpiredWeightedAverageRemainingContractualTerm
P0Y
fwbi Class Of Warrant Or Right Expired Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExpiredWeightedAverageRemainingContractualTerm
P0Y
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1560998
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4741964
dei Entity Registrant Name
EntityRegistrantName
Entero Therapeutics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001604191
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4741964
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1560998
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.143
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.143
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.143
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37853
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4993860
dei Entity Address Address Line1
EntityAddressAddressLine1
777 Yamato Road, Suite 502
dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33431
dei City Area Code
CityAreaCode
561
dei Local Phone Number
LocalPhoneNumber
589-7020
dei Entity Information Former Legal Or Registered Name
EntityInformationFormerLegalOrRegisteredName
First Wave BioPharma, Inc.
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ENTO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4754030
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
366788
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3711770
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
305461
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1244466
CY2024Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
83170009
CY2024Q3 us-gaap Assets Current
AssetsCurrent
83842258
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4956236
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14565
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
21520
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
21522
CY2024Q3 us-gaap Goodwill
Goodwill
1684182
CY2023Q4 us-gaap Goodwill
Goodwill
1684182
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
144410
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
195440
CY2024Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128250
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
11250
CY2024Q3 fwbi Assets Noncurrent Excluding Property Plant And Equipment Net
AssetsNoncurrentExcludingPropertyPlantAndEquipmentNet
1978362
CY2023Q4 fwbi Assets Noncurrent Excluding Property Plant And Equipment Net
AssetsNoncurrentExcludingPropertyPlantAndEquipmentNet
1912394
CY2024Q3 us-gaap Assets
Assets
85820620
CY2023Q4 us-gaap Assets
Assets
6883195
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2214946
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
554277
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
219193
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
825290
CY2024Q3 us-gaap Dividends Payable Current
DividendsPayableCurrent
1258450
CY2023Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
1069616
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
612784
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
79454
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
67111
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4239
CY2024Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
11918261
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
15690304
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3133317
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
80213
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
146949
CY2024Q3 us-gaap Liabilities
Liabilities
15770517
CY2023Q4 us-gaap Liabilities
Liabilities
3280266
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
61681100
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4741964
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1560998
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
474
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
156
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
198518268
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
187931445
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-190149739
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-184328672
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
8369003
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3602929
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85820620
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6883195
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
206999
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1011055
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
882522
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3725833
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1685608
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2422082
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13535241
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7951373
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
1892607
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3433137
us-gaap Operating Expenses
OperatingExpenses
14417763
us-gaap Operating Expenses
OperatingExpenses
11677206
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1892607
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3433137
us-gaap Operating Income Loss
OperatingIncomeLoss
-14417763
us-gaap Operating Income Loss
OperatingIncomeLoss
-11677206
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
-229
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1021
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
-675
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
13108
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2874
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7859
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3729
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2645
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1021
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7184
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16837
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1895252
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3434158
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14424947
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11694043
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10604640
CY2024Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1895252
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-3434158
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-3820307
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-11694043
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-685719
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-2000760
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2580971
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3434158
us-gaap Net Income Loss
NetIncomeLoss
-5821067
us-gaap Net Income Loss
NetIncomeLoss
-11694043
CY2024Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
84632
CY2023Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
49292
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
150776
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
231047
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2665603
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3483450
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5971843
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11925090
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4552019
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4552019
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
378301
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
378301
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3005055
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3005055
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
188175
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
188175
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.21
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.99
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-63.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-63.37
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.15
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.15
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.67
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.67
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
9120595
CY2024Q3 fwbi Deemed Dividend Of Series B Preferred Stock
DeemedDividendOfSeriesBPreferredStock
84632
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
183646
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2580971
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
8369003
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
881960
CY2023Q3 fwbi Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
267
CY2023Q3 fwbi Deemed Dividend Of Series B Preferred Stock
DeemedDividendOfSeriesBPreferredStock
49292
CY2023Q3 fwbi Stock And Warrants Issued During Period Value Issued For Services
StockAndWarrantsIssuedDuringPeriodValueIssuedForServices
76000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
263330
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3434158
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3278805
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3602929
fwbi Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
4495526
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
2300500
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
120648
fwbi Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
45
fwbi Deemed Dividend Of Series B Preferred Stock
DeemedDividendOfSeriesBPreferredStock
188834
fwbi Stock And Warrants Issued During Period Value Issued For Services
StockAndWarrantsIssuedDuringPeriodValueIssuedForServices
1541995
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
586896
us-gaap Net Income Loss
NetIncomeLoss
-5821067
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
8369003
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2742152
fwbi Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
657
fwbi Deemed Dividend Of Series B Preferred Stock
DeemedDividendOfSeriesBPreferredStock
231047
fwbi Stock And Warrants Issued During Period Value Issued For Services
StockAndWarrantsIssuedDuringPeriodValueIssuedForServices
76000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
914350
us-gaap Net Income Loss
NetIncomeLoss
-11694043
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3278805
us-gaap Net Income Loss
NetIncomeLoss
-5821067
us-gaap Net Income Loss
NetIncomeLoss
-11694043
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
48946
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21955
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
5848
fwbi Change In Right Of Use Assets
ChangeInRightOfUseAssets
55262
fwbi Change In Right Of Use Assets
ChangeInRightOfUseAssets
47429
us-gaap Share Based Compensation
ShareBasedCompensation
586896
us-gaap Share Based Compensation
ShareBasedCompensation
914350
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1541995
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
76000
fwbi Issuance Of Common Stock To Financial Advisors At Acquisition
IssuanceOfCommonStockToFinancialAdvisorsAtAcquisition
120648
fwbi Issuance Of Preferred Stock To Financial Advisors At Acquisition
IssuanceOfPreferredStockToFinancialAdvisorsAtAcquisition
3890626
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
10604640
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-93014
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-939005
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1272558
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-58004
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-48919
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
117000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-6899
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
900546
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-140749
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-531127
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
514364
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-4239
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1332
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9046305
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8938474
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
88169
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
88169
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
4495526
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
5525010
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1730365
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5946383
fwbi Proceeds From Exercise Of Pre Funded Warrants
ProceedsFromExerciseOfPreFundedWarrants
45
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-644582
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-603494
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
31798
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5613152
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10867899
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3344984
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1929425
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3733292
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1384423
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
388308
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3313848
us-gaap Interest Paid Net
InterestPaidNet
30468
us-gaap Interest Paid Net
InterestPaidNet
15414
fwbi Fair Value Of Common Shares Issued In Acquisition Net Of Cash
FairValueOfCommonSharesIssuedInAcquisitionNetOfCash
-152331
fwbi Fair Value Of Preferred Stock Issued In Acquisition Net Of Cash
FairValueOfPreferredStockIssuedInAcquisitionNetOfCash
-57790474
fwbi Options Assumed
OptionsAssumed
-1271000
fwbi Warrants Assumed
WarrantsAssumed
-789000
CY2024Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
188834
CY2023Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
231047
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
400000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-190100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates.</p>
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000.00
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000.00
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. At September 30, 2024 the Company had approximately $0.4 million in one account in the U.S. which was in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company mitigates its risk by maintaining the majority of its cash and equivalents with high quality financial institutions.</p>
CY2024Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
400000
CY2023Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
612784
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
87818
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
87818
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
87818
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
73253
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14565
CY2024Q3 us-gaap Depreciation
Depreciation
1000
CY2023Q3 us-gaap Depreciation
Depreciation
7000
us-gaap Depreciation
Depreciation
15000
us-gaap Depreciation
Depreciation
22000
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment Current
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
16000
CY2023Q3 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment Current
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
0
CY2022Q4 us-gaap Goodwill
Goodwill
1684182
CY2023Q4 us-gaap Goodwill
Goodwill
1684182
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
16683498
us-gaap Goodwill Transfers
GoodwillTransfers
-16683498
CY2024Q3 us-gaap Goodwill
Goodwill
1684182
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-31598
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
338402
CY2024Q3 fwbi Intangible Assets Reclassified To Assets Held For Sale
IntangibleAssetsReclassifiedToAssetsHeldForSale
63338402
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
215531
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
253577
CY2023Q4 fwbi Consulting Fees
ConsultingFees
75972
CY2024Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
3662
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
495741
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
219193
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
825290
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Accrued Liabilities
DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities
2200000
CY2023Q3 us-gaap Disposal Group Including Discontinued Operation Accrued Liabilities
DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities
0
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4741964
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1560998
CY2024Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1000
fwbi Stock Cancelled During Period Shares Acquisitions
StockCancelledDuringPeriodSharesAcquisitions
148
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1779780
CY2023Q4 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
19.29
CY2023 fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P4Y11M26D
fwbi Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
5226498
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted
1.87
fwbi Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm
P4Y10M6D
fwbi Class Of Warrant Or Right Shares Assumed From Business Acquisition
ClassOfWarrantOrRightSharesAssumedFromBusinessAcquisition
127680
fwbi Class Of Warrant Or Right Weighted Average Exercise Price Assumed From Business Acquisition
ClassOfWarrantOrRightWeightedAverageExercisePriceAssumedFromBusinessAcquisition
3.48
fwbi Class Of Warrant Or Right Assumed Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightAssumedWeightedAverageRemainingContractualTerm
P8Y5M19D
fwbi Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
3
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired
-52500.00
fwbi Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
2206199
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
-3.99
fwbi Class Of Warrant Or Right Exercised Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm
P8Y6M29D
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4927756
CY2024Q3 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
7.21
fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P4Y11M15D
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
108797
CY2022Q4 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
383.20
CY2022 fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P5Y6M
fwbi Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
1369940
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted
14.60
fwbi Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm
P4Y7M2D
fwbi Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
4
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired
-15475.80
fwbi Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
580293
fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
-19.20
fwbi Class Of Warrant Or Right Exercised Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm
P4Y8M19D
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
898440
CY2023Q3 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
47.60
fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P4Y10M20D
fwbi Class Of Warrant Or Right Shares Assumed From Business Acquisition
ClassOfWarrantOrRightSharesAssumedFromBusinessAcquisition
127680
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
183646
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
263330
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
586896
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
914350
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
78000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
600000
CY2024Q3 fwbi Number Of Real Property Operating Leases
NumberOfRealPropertyOperatingLeases
2
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
55000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
42000
us-gaap Operating Lease Expense
OperatingLeaseExpense
136000
us-gaap Operating Lease Expense
OperatingLeaseExpense
114000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M24D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0700
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
21815
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
88788
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
60593
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
171196
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11529
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
159667
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
612784
us-gaap Repayments Of Debt
RepaymentsOfDebt
6891658
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
644582
CY2024Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
456123
fwbi Debt Instrument Transfers To Liabilities Held For Sale
DebtInstrumentTransfersToLiabilitiesHeldForSale
6403737
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17519250
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
900852
us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.06
CY2024Q3 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
17000
CY2023Q3 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
21000
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
84000
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
68000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.73
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
fwbi Income Tax Benefits
IncomeTaxBenefits
-10600000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-001914-index-headers.html Edgar Link pending
0001410578-24-001914-index.html Edgar Link pending
0001410578-24-001914.txt Edgar Link pending
0001410578-24-001914-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20240930.xsd Edgar Link pending
tmb-20240930x10q.htm Edgar Link pending
tmb-20240930xex31d1.htm Edgar Link pending
tmb-20240930xex31d2.htm Edgar Link pending
tmb-20240930xex32d1.htm Edgar Link pending
tmb-20240930_cal.xml Edgar Link unprocessable
tmb-20240930_def.xml Edgar Link unprocessable
tmb-20240930x10q_htm.xml Edgar Link completed
tmb-20240930_lab.xml Edgar Link unprocessable
tmb-20240930_pre.xml Edgar Link unprocessable